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Summary: Neutrophils play a major role in the host defence by producing reactive oxygen species. These products
are liberated by activated cells and are known to cause endothelial cell injury and damage. The present study shows
that low-density lipoproteins increase Superoxide anion production by twofold in polymorphonuclear leukocytes
stimulated by formyl-Met-Leu-Phe in vitro. Moreover, LDL induced a large increase in phosphoinositides and
cytosolic-free calcium. Data from experiments performed on neutrophils treated with pertussis toxin, staurosporine,
propranolol or nifiumic acid suggest that modulation of phospholipase D and A2 activities could be involved in the
modification by LDL of leukocyte response to formyl-Met-Leu-Phe. LDL lipid moiety could play a key role in
their action on polymorphonuclear functions because cholesterol was exchanged between lipoproteins and cells that
can modify membrane fluidity and interact with the formyl-Met-Leu-Phe receptor.
Introduction
Dyslipoproteinaemia, demonstrating increased blood li-
poprotein concentrations, hypertension and tabagism, is
often associated with accelerated atherogenesis mecha-
nisms (1, 2). Increased lipoprotein concentrations, and
especially high low-density lipoprotein (LDL) concen-
trations, could modify polymorphonuclear leukocyte
(PMN) functions. Some authors have reported the en-
hanced oxidative metabolism of polymorphonuclear
neutrophils isolated from hyperlipoproteinaemic sub-
jects and an inhibition of polymorphonuclear neutrophil
phagocytosis following their treatment with LDL in vi-
tro (3, 4).
In a previous study, we demonstrated that LDL stimu-
lates Superoxide (O^") generation by human polymor-
phonuclear neutrophil in vitro (5). This effect is concen-
tration dependent and might mediate venous endothelial
structure injury by arachidonic acid metabolites, proteo-
lytic enzymes and reactive oxygen species released by
activated polymorphonuclear neutrophils (6—10). More-
over, they might enhance LDL oxidation and contribute
to the formation of foam cells mainly implicated in the
atherogenic process (11 — 13).
The oxidative burst results from the assembly and acti-
vation of the NADPH oxidase, a transmembrane
electron transport chain which reduces oxygen to super-
oxide (14, 15). This (Oi~ generation is initiated in neu-
trophils by a variety of agonists (16). Among them is
the formyl-Methionyl-Leucyl-Phenylalanine, a tripep-
tide analogous to bacterial wall constituents, and cur-
rently being used for in vitro experiments. Polymorpho-
nuclear neutrophil activation by formyl-Met-Leu-Phe
triggers a cascade of tightly controlled biochemical
events leading to an oxidative burst (17—19). The first
step consists of the ligand binding to specific cell sur-
face receptors. Among them is the formyl-Met-Leu-Phe
receptor which is well-characterized and coupled to cel-
lular responses through a pertussis toxin-inhibitable G
protein (20). Three phospholipases are mainly involved
at different steps of neutrophil activation; phospholipase
C, phospholipase A2 and phospholipase D. Hydrolysis
of membrane phospholipids leads to the formation of
numerous bioactive lipids. These pathways were impli-
cated in the signal transduction of polymorphonuclear
neutrophil activated by formyl-Met-Leu-Phe (18, 21).
In order to clarify LDL effects of formyl-Met-Leu-Phe-
induced polymorphonuclear neutrophil oxidative burst,
we investigated in vitro the action of pharmacological
tools on some steps of transduction leading to the oxida-
tive burst of polymorphonuclear neutrophil.
Materials and Methods
Reagents
Pertussis toxin (lot 72H-0641-1), staurosporine, propranolol,
nifiumic acid, and formyl-Met-Leu-Phe were purchased from
Sigma Chemical Co. (Saint-Louis MO, USA).
Stock solutions of formyl-Met-Leu-Phe (1 mmol/l) and stauro-
sporine (1 mmol/l) were prepared in dimethyl sulphoxide and
stored at -20 °C.
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Stock solution of propranolol (50 mmol/1) was prepared in phos-
phate buffered saline without Ca2+ and Mg2"1" and stored at
-20 °C.
Dilutions of stock solutions were made in phosphate buffered sa-
line for each experiment.
Lipoprotein isolation
LDL (1.030 < d < 1.050 kg/1) was prepared from the serum of
normolipaemic subjects (3.5 mmol/1 < total cholesterol < 6.5
mmol/1 and triacylglyerols < 1.0 mmol/1) in the presence of ethyl-
enediaminetetraacetic acid (2.69 μπιοΐ/ΐ) and phenylmethylsulpho-
nyl fluoride (0.1 mmol/1) to prevent both action of lipolytic en-
zymes and endogenous proteases and to avoid oxidation. Isolation
of LDL was achieved through two successive ultracentrifugation
steps at 100 000 g for 18 hours at 4 °C. It was then dialyzed ex-
haustively against the phosphate buffer and stored for less than five
days under nitrogen at 4 °C after sterilization by filtration (0.22
urn Millipore). The purity of the LDL fraction was assayed by SDS
polyacrylamide gel electrophoresis. Since the main constituent of
LDL is cholesterol, LDL concentration was expressed as LDL cho-
lesterol in mmol/1.
Cell preparation
The cells were isolated from heparinized (10000 U/l) peripheral
blood of healthy volunteers from the laboratory population, by suc-
cessive use of Ficoll-Hypaque and polyvinylalcohol (22). After iso-
lation, the cells were put in a phosphate buffered solution for deter-
mination of Superoxide generation and viability was assessed
through a trypan blue exclusion test.
Superoxide production
Superoxide production was measured in terms of ferricytochrome c
reduction as previously described (5, 23). The stimulating agent
was formyl-Methionyl-Leucyl-Phenylalanine 100 nmol/1. The re-
sults were expressed as O^ release in mmol/106 cells.
Phospholipid turnover analysis
Polymorphonuclear neutrophil labelling
After isolation, polymorphonuclear neutrophil cell count was ad-
justed to 1010/1 in Hank's balanced salt solution containing 20
mmol/1 Hepes, pH = 7.4, supplemented with 250 mg/1 bovine se-
rum albumin as previously described (24). Cells were labelled with
7.4 GBq/1 (200 mCi/1) of Hiyo-[2-3H]inositol and incubated for
16-20 h at 37 °C with gentle shaking.
At the end of incubation, cells were washed three times, counted
and put in the same Hank's solution, supplemented with 1 g/1 bo-
vine serum albumin and 10 mmol/1 LiCl (for inhibiting the en-
zymes of inositol phosphate dephosphorylation). Cells were ad-
justed to a concentration of 107 cells per 600 μΐ aliquots and incu-
bated for 10 min at 37 °C before the stimulation.
Polymorphonuclear neutrophil stimulation
Stimulating agents were applied to aliquots tested in duplicate, as
follows:
— phosphate buffered saline for 15 s (controls)
- formyl-Met-Leu-Phe from 10~9 to 10~6 mol/1 for 15 s
- LDL (2.5 mmol/1) for 5 min
— LDL (2.5 mmol/1) for 5 min before the addition of formyl-Met-
Leu-Phe for 15 s.
The reaction was stopped by addition of perchloric acid, followed
by three cycles of freezing-thawing.
After centrifugation, the hydrosoluble perchloric acid precipitation
supernatants containing inositol phosphates were diluted and neu-
tralized. The inositol lipids were extracted from the perchloric acid
insoluble pellets, dried and deacylated by alkaline hydrolysis as
described by Creba et al. (25) and Poggioli et al. (26). The
[3H]inositol phosphates and [3H]glycerophosphoryl esters were
then separated by anion-exchange chromatography on Dowex
AG1-X8 columns using the buffer system described by Downes et
al. (27) and Berridge et al. (28).
Cytosolic-free calcium concentrations
Changes in cytosolic free calcium concentration were measured in
polymorphonuclear neutrophil loaded with 1 umol/l Fura 2/AM at
37 °C for 45 min (29, 30). Cells were then washed and suspended
in 10 mmol/1 HEPES/Hank's balanced salt solution. Fura 2 fluores-
cence assays were performed with aliquots of 5 Χ 106 polymor-
phonuclear neutrophil in 2 ml Hank's balanced salt solution, using
a fluorimeter (Jobin Yvon 3D, France) equipped with a thermally
controlled cuvette holder and a magnetic stirrer. Various concentra-
tions of LDL were tested: 0.01 to 5 mmol/1 cholesterol. Excitation
and emission wavelengths for Fura 2 fluorescence assays were 340
and 510 nm, respectively. Cytosolic calcium concentrations were
calculated as described (30).
Intracellular level of polymorphonuclear neutrophil
cholesterol
Polymorphonuclear neutrophils were preincubated in duplicate at
37 °C for 5 min and placed in contact with increasing concentra-
tions of LDL for 15 min. Superoxide generation was measured in
half of the tubes and cellular cholesterol content was measured in
the other. In these tubes, ferricytochrome c was omitted. After stop-
ping the reaction in an ice-water bath, the cells were washed three
times in phosphate buffered saline before freezing.
After lipid extraction from neutrophils, cellular cholesterol mea-
surement was performed by gas chromatography coupled with
mass spectrometry. This measurement was performed in the Labor-
atoire de Biochimie des Lipoproteines de Dijon (Service du Pr
Gamberf).
Statistical analysis
The Mann-Whitney's test and the Wilcoxon's test were used for the
comparison of unpaired and paired quantitative variables.
Results
After polymorphonuclear neutrophil preincubation for
5 min at 37 °C with buffer or LDL, Superoxide pro-
duction was assayed over the next 5 min in the presence
of formyl-Met-Leu-Phe 100 nmol/1.
In the presence of LDL, formyl-Met-Leu-Phe-induced
stimulation was increased twofold (Wilcoxon's test:
p < 0.01) (control: Oi~ 6.72 ±1.65 nmol/106 cells;
with LDL at 2.5 mmol/1: Ο^~ 14.92 ± 2.19 nmol/106
cells; with LDL at 5 mmol/1: ΟΓ 16.59 ±2.18 nmol/
106 cells; means ± SEM, n = 9).
Pertussis toxin action
Preincubation with pertussis toxin (1 μg for 2 X 107
cells) drastically impaired polymorphonuclear neutro-
phil response by ADP-ribosylation of G-protein (31).
There was a variability in the activity of pertussis toxin
depending on the batch purchased, but the maximal ef-
fect was observed with polymorphonuclear neutrophil
treated for 2 h in Hank's solution under shaking, as pre-
viously described by Gabig et al. (32) and Omann et al.
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(33). After centrifugation, cells were washed before their
stimulation by formyl-Met-Leu-Phe with or without
LDL. The cells' response to formyl-Met-Leu-Phe was
inhibited after pertussis toxin treatment, in the absence
(polymorphonuclear neutrophils + formyl-Met-Leu-
Phe: O2~ 14.37 ± 0.83 nmol/106 cells; polymorphonu-
clear neutrophils + pertussis toxin + formyl-Met-Leu-
Phe: O2~ 3.28 ± 1.38 nmol/106 cells; means ± SEM,
n = 3) or in the presence of LDL (polymorphonuclear
neutrophils + LDL + formyl-Met-Leu-Phe: O2~ 18.45
± 0.67 nmol/106 cells; polymorphonuclear neutrophils
+ pertussis toxin + LDL + formyl-Met-Leu-Phe: O2~
3.72 ± 1.44 nmol/106 cells).
Effects of LDL on phosphatidyl turnover
Polymorphonuclear neutrophil incubation with LDL at
a concentration of 2.5 mmol/1 induced a large increase
in phosphoinositides, and particularly in phosphatidyli-
nositol 4,5-bisphosphate along with inositol 1,4,5-tris-
phosphate (fig. 1). Polymorphonuclear neutrophil incu-
bation with formyl-Met-Leu-Phe induced, as expected,
an activation of phosphatidylinositol 4,5-bisphosphate
breakdown and formation of inositol 1,4,5-trisphos-
phate.
Stimulation of polymorphonuclear neutrophils by for-
myl-Met-Leu-Phe in the presence of LDL also led to an
increase of phosphatidylinositol 4,5-bisphosphate in all
the LDL or formyl-Met-Leu-Phe concentrations used
(tab. 1).
Effect of LDL on calcium mobilization
The intracellular Ca2+ mobilization, measured as Fura 2
fluorescence intensity, increased with LDL concentra-
tions (fig. 2). At the lowest LDL concentration, the
kinetics were similar to those obtained by formyl-Met-
Leu-Phe stimulation. At LDL concentrations above 0.5
mmol/1 cholesterol, kinetics were the same as those ob-
tained after polymorphonuclear neutrophil stimulation
by a particular agent, such as opsonized zymosan. Bo-
vine albumin at concentrations from 0.1 to 1.0 mg/1 in-
duced less than 1/10 of the increase in Fura 2 fluores-
cence intensity induced by LDL at respective protein
concentrations.
Staurosporine effect
At a concentration of 100 nmol/1, Staurosporine showed





























Fig. 1 Variation of phosphoinositides and inositol phosphates of polymorphonuclear neutrophils
stimulated with formyl-Met-Leu-Phe or LDL.
Mean ± SEM * significantly different from control p ^ 0.05
Wilcoxon's test for a paired series (n = 10) ** significantly different from control p s 0.01
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Tab. 1 Effects of LDL on polymorphonuclear neutrophil stimulation by formyl-Met-Leu-Phe.






























































phonuclear neutrophil stimulation (polymorphonuclear
neutrophils + formyl-Met-Leu-Phe: ΟΓ 2.58 ± 0.92
nmol/106 cells; polymorphonuclear neutrophils + staur-
osporine + formyl-Met-Leu-Phe: O^ 6.37 ± 2.06
nmol/106 cells; means ± SEM, n = 3).
Staurosporine did not significantly modify the LDL ef-
fect on the polymorphonuclear neutrophil response to
formyl-Met-Leu-Phe (polymorphonuclear neutrophils +
LDL + formyl-Met-Leu-Phe: Oi~ 8.12 ± 1.91 nmol/106
cells; polymorphonuclear neutrophils + Staurosporine +
LDL + formyl-Met-Leu-Phe: Oi~ 8.87 ± 2.29 nmol/
IO6 cells).
Propranolol effect
Polymorphonuclear neutrophil preincubation for 5 min
at 37 °C with phosphate buffer or with various concen-
trations of propranolol, ranging from 0.05 mmol/1 to
5 mmol/1, was performed before the polymorphonuclear
neutrophil stimulation with LDL, formyl-Met-Leu-Phe
or LDL + formyl-Met-Leu-Phe.
Propanolol exerted a potent stimulating effect at a con-
centration of 0.5 mmol/1 but an inhibiting effect at the
highest concentration (5 mmol/1).
LDL added their proper effect to that exerted by formyl-
Met-Leu-Phe (fig. 3a).
Niflumic acid effect
Niflumic acid had no effect on polymorphonuclear neu-
trophil stimulation by LDL. When the cells were prein-
cubated for 5 min at 37 °C with various concentrations







Fig. 2 Effect of LDL on cytosolic-free calcium concentration in
polymorphonuclear neutrophils. Calcium concentration stated
above the peaks was calculated from Fura 2 fluorescence intensity
using the formula: [Ca2+] nmol/1 = 224 (F - Fmin)/(Fmax - F)
where Fmin and Fmax were the fluorescence intensity measured on
unstimulated and on Triton X-100 treated polymorphonuclear neu-
trophils respectively. A representative experiment out of three is
shown.

















Fig. 3 Effect of propranolol (a) and niflumic acid (b) on polymor-
phonuclear neutrophil stimulation by formyl-Met-Leu-Phe and
LDL.
Concentrations of propranolol used:
ffl control, E2 0.05 mmol/1, B 0.5 mmol/1, W 5 mmol/1
Concentrations of niflumic acid used:
• control, 0 88.6 μτηοΐ/l, Β 0.5 mmol/1, W 886 μτηοΐ/l,
m 1772 μηιοΙ/1
Result of one representative experiment
1772 μπιοΙ/1) before the addition of formyl-Met-Leu-
Phe, an inhibiting effect was observed for concentrations
higher than 88.6 μηιοΐ/ΐ. LDL potentiated the formyl-
Met-Leu-Phe stimulating effect and added their proper
stimulating effect to the response of control cells incu-
bated in phosphate buffered saline (fig. 3b).
Intracellular cholesterol content
In the presence of LDL (0.25-1 mmol/1 cholesterol) a
concentration-dependent increase of polymorphonuclear
neutrophil cholesterol content was observed (Mann-
Whitney test: ρ < 0.05) (fig. 4).
Discussion
This study has shown that LDL, at physiological con-
centrations, interacts with polymorphonuclear neutrophil
stimulation either directly by its own stimulating effect
or indirectly by modification of the response to formyl-
Met-Leu-Phe.
In previous work (5), a slight enhancement of the bind-
ing of formyl-Met-Leu-Phe to its specific membrane re-
ceptors was observed in the presence of LDL which may
induce an increase in Oi~ released in response to for-
myl-Met-Leu-Phe. Because LDL did not interfere with
pertussis toxin inhibitable G proteins, they also might
have a "priming" effect which can potentiate the
NADPH oxidase stimulation by formyl-Met-Leu-Phe
(34) rather than increase the number or affinity of the
formyl-Met-Leu-Phe receptors.
Phospholipase C activity was investigated by means of
inositol phosphate measurement and a phosphoinositide
metabolism study. We observed a highly significant
increase of phosphatidylinositol 4,5-bisphosphate
content which could not be due to an accelerated inositol
turnover because dephosphorylating enzymes were in-
hibited by the lithium added to the incubation buffer.
However, it is possible that tritiated inositol, in excess
in the cell medium, conjugated to CMP-activated phos-
phatidic acid was able to replenish membrane stocks of
phosphatidyl inositol (phosphates). This phenomenon
might be due to phospholipase D activation by LDL,
leading to an increased generation of phosphatidic acid.
This activation may be greater than that of phospholi-
pase C inducing a relatively weak enhancement of inosi-
tol 1,4,5-trisphosphate release. Inositol 1,4,5-trisphos-.
phate is released into the cytosol, binds to specific re-
ceptors on intracellular Ca2+ storage organelles and in-
duces the release of calcium. In our study, the
intracellular calcium mobilization, measured as Fura 2
fluorescence intensity, increased with LDL concentra-







Fig. 4 Cellular cholesterol content of polymorphonuclear neutro-
phils after contact of 15 min with LDL at different concentrations.
Mean ± SEM; one experiment in triplicate
Mann-Whitney's test for non-paired values
* significantly different from control (p ̂  0.05)
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0.5 mmo/1, Fura 2 fluorescence was sustained even in
an incubation medium without calcium and in the pres-
ence of EGTA (data not shown). These data suggest that
the calcium efflux could be decreased by LDL. To the
best of our knowledge, there is no previous study on the
effect of LDL on polymorphonuclear neutrophil phos-
phoinositide metabolism. However Block et al. (35) have
already described a stimulation of the phosphatidylinosi-
tol cycle by LDL in human platelets, lymphocytes and
fibroblasts.
Protein kinase C, a phospholipid/Ca2+-dependent ki-
nase, is a key enzyme in the regulation of intracellular
signal transduction. Staurosporine, an alkaloid extracted
from Streptomyces, was described by Tamaoki et al. (36)
as a protein kinase C inhibitor. These authors have sug-
gested that Staurosporine interacts directly with protein
kinase C and this hypothesis has been corroborated by
Nakadate et al. (37) who have shown that Staurosporine
interacts at the active site of the catalytic fragment of
protein kinase C. Staurosporine is one of the most potent
inhibitors, active at nanomolar concentrations, but de-
monstrates similar affinities for protein kinase C, tyro-
sine kinases and c-AMP-dependent protein kinase (38,
39). In our previous experiments, polymorphonuclear
neutrophil stimulation by phorbol myristate acetate was
inhibited 90% by Staurosporine, 100 nmol/1. However,
the effect of LDL on polymorphonuclear neutrophil does
not seem to be directly and exclusively protein kinase
C-dependent because in the present study it was not in-
hibited by staurosporine.
Nevertheless, staurosporine exerts several effects on
polymorphonuclear neutrophil activation. This sub-
stance at a concentration of 100 nmol/1 potentiates poly-
morphonuclear neutrophil stimulation by formyl-Met-
Leu-Phe (40) and inhibits Superoxide generation at
higher concentrations. These effects might depend on
the length of polymorphonuclear neutrophil treatment
with staurosporine. Combadiere et al. reported 125%
O2~ production compared to the control (41) while we
found a 200% increase in O2~ production by polymor-
phonuclear neutrophil incubation 10 min with stauro-
sporine before the addition of formyl-Met-Leu-Phe.
Likewise, an increase of phosphatidic acid release was
shown by Reinhold et al. (42) and Perianin et al. (43).
Recently, Mori et al. (44) have shown that enhancement
of Superoxide production by staurosporine 100 nmol/1
via phospholipase D activation in formyl-Met-Leu-Phe-
stimulated polymorphonuclear neutrophils was the result
of an increase in diacylglycerol production through
phosphatidic acid.
Considering the phopsholipase D activation already de-
scribed with staurosporine, we hypothesize that the ef-
fects of LDL treatment on polymorphonuclear neutro-
phil phosphoinositide metabolism could be explained by
a similar mechanism.
In formyl-Met-Leu-Phe-activated polymorphonuclear
neutrophils, phosphatidylcholine is the phospholipase D
substrate generating phosphatidic acid which in turn leads
to a diacylglycerol release after its dephosphorylation by
phosphatidate phosphohydrolase. Rossi et al. have shown
that this enzyme was inhibited by propranolol (45). In the
same experimental conditions as those used by these au-
thors, we showed an enhancement of O2~ generation
which is for English et al. (46) correlated to phosphatidic
acid release. However, Agwu et al. have shown that poly-
morphonuclear neutrophil stimulation by formyl-Met-
Leu-Phe was counteracted by high a propranolol concen-
tration (5 mmol/1) which inhibited phospholipase D (47).
Under the same experimental conditions, we observed
that LDL did not modify the propranolol effect.
In formyl-Met-Leu-Phe-stimulated human neutrophils,
protein kinase C-independent activation mechanisms
have been suggested and M ller & Nigam (48) have
shown that staurosporine enhances arachidonic acid and
platelet activation, and leukotriene B4 release. We have
thus tested the activity of niflumic acid, a non-steroidal
anti-inflammatory drug, on polymorphonuclear neutro-
phil activation. According to Abramson et al. (49) vari-
ous concentrations of niflumic acid inhibited formyl-
Met-Leu-Phe-induced O2~ generation in a concentration-
dependent manner. Nevertheless, niflumic acid did not
inhibit the LDL-induced polymorphonuclear neutrophil
oxidative metabolism and even the lowest concentration
used (88.5 μπιοΙ/1) potentiated an LDL effect, probably
by stimulating phospholipase A2, which leads to arachi-
donic acid accumulation.
LDL is able to modify in vitro the polymorphonuclear
neutrophil oxidative metabolism either by a direct stimu-
lating effect or by alteration of the polymorphonuclear
neutrophil response to formyl-Met-Leu-Phe by an action
which could involve phospholipase D and phospholipase
A2 activations.
The LDL structure plays a main role in its action of
polymorphonuclear neutrophil functions. LDL modifies
cell lipid content, since a concentration-dependent
increase in cholesterol level was observed after incuba-
tion of polymorphonuclear neutrophil with increasing
LDL concentrations. We have previously demonstrated
(5) that LDL from hypertriglyceridaemic subjects stim-
ulated the polymorphonuclear neutrophil oxidative me-
tabolism and inhibited polymorphonuclear neutrophil
chemotaxis less than LDL from normolipaemic subjects
whose composition is different. Moreover, LDL trypsi-
nation experiments showed that the lipid moiety is
mainly responsible for the described effects of LDL on
polymorphonuclear neutrophil migration (5). These ob-
servations, added to the fact that the polymorphonuclear
neutrophil cholesterol amount increases after the incuba-
tion of these cells with increasing LDL concentrations,
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suggest that lipid exchanges between lipoproteins and
cell membranes might appear and modify the membrane
fluidity. These modifications could alter formyl-Met-
Leu-Phe receptor expression and affinity. This hypothe-
sis was corroborated upon viewing the alteration of for-
myl-Met-Leu-Phe binding on polymorphonuclear neu-
trophils extracted from hyperlipidaemic type lib pa-
tients (50).
In spite of their short half-life, polymorphonuclear
neutrophils could be involved in atherogenic states
because they display, in their excited state, a great
source of free radicals involved in endothelial injuries.
LDL are transported into the intimal layer through the
endothelium (51) and their concentration in the arterial
intima is three times greater than in plasma (52). The
polymorphonuclear neutrophils present in the intima
may be activated by LDL. Activated neutrophils might
produce oxygen free radicals and therefore modify
LDL but they are found in small numbers in the
atherosclerotic intima (53). However it has been
shown in rabbits fed a high cholesterol diet that poly-
morphonuclear neutrophils were the most numerous
cells at the beginning of the atheromateous process,
and were soon replaced by monocytes and lympho-
cytes (54). Therefore it seems particularly interesting
to study the interaction between polymorphonuclear
neutrophils and lipoproteins during the early stages of
atherogenesis in animal models.
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